Evidence map›Paper›PMID 27656552›Full record

ArticleJournal of clinical and diagnostic research : JCDR2016

Effect of Alendronate with β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial.

Rohini Naineni, Vishali Ravi, Dwijendra Kocherlakota Subbaraya, Jammula Surya Prasanna, Veerendranath Reddy Panthula, Rekha Rani Koduganti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and diagnostic research : JCDR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Dental alloplastic bone substitutes currently available in Korea.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2019
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rohini NaineniReader, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre , Hyderabad, Telangana, India .
Vishali RaviSenior Lecturer, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre , Hyderabad, Telangana, India .
Dwijendra Kocherlakota SubbarayaProfessor and Head, Department of Pedodontics, MNR Dental College and Hospital , Sangareddy, Telangana, India .
Jammula Surya PrasannaProfessor, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre , Hyderabad, Telangana, India .
Veerendranath Reddy PanthulaProfessor, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre , Hyderabad, Telangana, India .
Rekha Rani KodugantiProfessor and Head, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre , Hyderabad, Telangana, India .
Kamineni Institute of Dental Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlendronate (ALN), an aminobisphosphonate, inhibits osteoclastic bone resorption and also stimulates osteogenesis. Beta-Tricalcium Phosphate (β-TCP) is an osteoconductive graft material which provides a scaffold for bone formation and also a widely used drug delivery vehicle for growth factors and antibiotics. Drug delivery vehicles, like β-TCP, improve the potency of the drugs by specific local site delivery of the drug, optimal release characteristics and easy handling.

aimThe aim of the this study was to evaluate the bone formation potential of 400μg ALN delivered in β-TCP in the treatment of periodontal intra-osseous defects. MATERIALS AND

methodsThirty patients with periodontal defects were randomly assigned to 400μg ALN + β-TCP + Saline (test) group and β-TCP + Saline (active-control) group. Clinical parameters like Clinical Attachment Level (CAL) gain, Probing Depth (PD) reduction, post-operative Gingival Recession (GR) were assessed from the baseline, 3 months and 6 months recordings. Radiographic parameters like Linear Bone Growth (LBG), Percentage Bone Fill (%BF), and change in alveolar crest height (ACH) were assessed from baseline and 6 months radiographs.

resultsMean measurements in the ALN test group for CAL gain (3.4 ± 0.74 mm), PD reduction (4.33 ± 0.82 mm), LBG (2.88 ± 0.88 mm), and %BF (51.98 ± 15.84%) were significantly greater with a p-value <0.05 compared to the mean measurements of CAL gain (2.20 ± 0.86 mm), PD reduction (3.20 ± 1.15 mm), LBG (1.70 ± 0.39 mm), and %BF (30.35 ± 6.88%) of the control group. There was mild alveolar crestal apposition (0.32 ± 0.68 mm) in the ALN test group and mild alveolar crestal resorption (-0.24 ± 0.40 mm) in the control group.

conclusion400μg ALN combined with β-TCP bone graft material was effective in improving soft tissue parameters, inhibiting alveolar crestal resorption and enhancing bone formation, compared to β-TCP alone.

Indexed as

Alveolar crestal resorptionBone formationDrug delivery vehicle

Identifiers

PMID27656552
PMCPMC5028499
OpenAlexW2519419678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.